Endothelin Receptors and Their Antagonists

Seminars in Nephrology

Volumn 35, Issue 2, 2015, Pages 125-136

  Maguire, Janet J ^a   Davenport, Anthony P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Ambrisentan; Antagonist; Bosentan; Endothelin 1; Macitentan; Sitaxentan

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; AMBRISENTAN; ATRASENTAN; AVOSENTAN; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; MACITENTAN; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N ACETYLENDOTHELIN 1 [6-21][11,15 ALANINE]; SARAFOTOXIN; SITAXSENTAN; SUCCINYLENDOTHELIN 1 [8-21][9 GLUTAMIC ACID 11,15 ALANINE]; TAK 044;

CHRONIC KIDNEY DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; HEPATITIS; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; LIVER FAILURE; LIVER TOXICITY; NATRIURESIS; NONHUMAN; NOSE OBSTRUCTION; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; REVIEW; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION; DRUG EFFECTS; HYPERTENSION, PULMONARY; METABOLISM; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ENDOTHELIN RECEPTOR ANTAGONISTS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION, PULMONARY; RECEPTORS, ENDOTHELIN; VASODILATION;

EID: 84929042854     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2015.02.002     Document Type: Review

References (83)

1. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
2. Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T., Goto K., et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 1989, 86:2863-2867.
3. Karet F.E., Davenport A.P. Localization of endothelin peptides in human kidney. Kidney Int 1996, 49:382-387.
4. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990, 348:730-732.
5. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990, 348:732-735.
6. Davenport A.P. International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev 2002, 54:219-226.
7. Davenport A.P., Maguire J.J. Endothelin. Handbk Exp Pharmacol 2006, 152:295-329.
8. Kohan D.E., Inscho E.W., Wesson D., Pollock D.M. Physiology of endothelin and the kidney. Compr Physiol 2011, 1:883-919.
9. Kohan D.E., Barton M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int 2014, 86:896-904.
10. Davenport A.P., Maguire J.J. Pharmacology of renal endothelin receptors. Contrib Nephrol 2011, 172:1-17.
11. Magure J.J., Davenport A.P. Endothelin@25-new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR review. Br J Pharmacol 2014, 17:5555-5572.
12. Kohan D.E., Cleland J.G., Rubin L.J., Theodorescu D., Barton M. Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve?. Life Sci 2012, 91:528-539.
13. Davenport A.P., Alexander S.P., Sharman J.L., Pawson A.J., Benson H.E., Monaghan A.E., et al. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev 2013, 65:967-986.
14. Southern C., Cook J.M., Neetoo-Isseljee Z., Taylor D.L., Kettleborough C.A., Merritt A., et al. Screening beta-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J Biomol Screen 2013, 18:599-609.
15. Meyer R.C., Giddens M.M., Schaefer S.A., Hall R.A. GPR37 and GPR37L1 are receptors for the neuroprotective and glioprotective factors prosaptide and prosaposin. Proc Natl Acad Sci U S A 2013, 110:9529-9534.
16. William D.L., Jones K.L., Pettibone D.J., Lis E.V., Clineschmidt B.V. Sarafotoxin S6c, an agonist which distinguishes between endothelin receptor subtypes. Biochem Biophys Res Commun 1991, 175:556-561.
17. Watakabe T., Urade Y., Takai M., Umemura I., Okada T. A reversible radioligand specific for the ETB receptor: [125I]Tyr13-Suc-[Glu9,Ala11,15]-endothelin-1(8-21), [125I]IRL 1620. Biochem Biophys Res Commun 1992, 185:867-873.
18. Ihara M., Saeki T., Fukuroda T., Kimura S., Ozaki S., Patel A.C., et al. A novel radioligand [125I]BQ-3020 selective for endothelin (ETB) receptors. Life Sci 1992, 51:PL47-PL52.
19. A) receptor. Life Sci 1992, 50:247-255.
20. Aramori I., Nirei H., Shoubo M., Sogabe K., Nakamura K., Kojo H., et al. Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected Chinese-hamster ovary cells. Mol Pharmacol 1993, 43:127-131.
21. Masuda Y., Sugo T., Kikuchi T., Kawata A., Satoh M., Fujisawa Y., et al. Receptor binding and antagonist properties of a novel endothelin receptor antagonist, TAK-044 [cyclo[D-alpha-aspartyl-3-[(4-phenylpiperazin-1-yl) carbonyl]-L-alanyl-L-alpha-aspartyl-D-2-(2-thienyl) glycyl-L-leucyl-D-tryptophyl]disodium salt], in human endothelinA and endothelinB receptors. J Pharmacol Exp Ther 1996, 279:675-685.
22. Ishikawa K., Ihara M., Noguchi K., Mase T., Mino N., Saeki T., et al. Biochemical and pharmacological profile of a potent and selective endothelinB-receptor antagonist, BQ-788. Proc Natl Acad Sci U S A 1994, 91:4892-4896.
23. Karet F.E., Davenport A.P. Human kidney: endothelin isoforms detected by HPLC with radioimmunoassay and receptor subtypes detected using ligands BQ123 and BQ3020. J Cardiovasc Pharmacol 1993, 22(Suppl 8):S29-S33.
24. Kuc R., Davenport A.P. Comparison of endothelin-A and endothelin-B receptor distribution visualized by radioligand binding versus immunocytochemical localization using subtype selective antisera. J Cardiovasc Pharmacol 2004, 44(Suppl 1):S224-S226.
25. Kuc R.E., Karet F.E., Davenport A.P. Characterization of peptide and nonpeptide antagonists in human kidney. J Cardiovasc Pharmacol 1995, 26(Suppl 3):S373-S375.
26. Karet F.E., Kuc R.E., Davenport A.P. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. Kidney Int 1993, 44:36-42.
27. Davenport A.P., Kuc R.E., Hoskins S.L., Karet F.E., Fitzgerald F. [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature. Br J Pharmacol 1994, 113:1303-1310.
28. Maguire J.J., Kuc R.E., O'Reilly G., Davenport A.P. Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro. Br J Pharmacol 1994, 113:49-54.
29. Maguire J.J., Davenport A.P. ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol 1995, 115:191-197.
30. Bohm F., Pernow J., Lindstrom J., Ahlborg G. ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. Clin Sci (Lond) 2003, 104:143-151.
31. Kaasjager K.A., Shaw S., Koomans H.A., Rabelink T.J. Role of endothelin receptor subtypes in the systemic and renal responses to endothelin-1 in humans. J Am Soc Nephrol 1997, 8:32-39.
32. Asano T.1, Ikegaki I., Suzuki Y., Satoh S., Shibuya M. Endothelin and the production of cerebral vasospasm in dogs. Biochem Biophys Res Commun 1989, 159:1345-1351.
33. Pierre L.N., Davenport A.P. Blockade and reversal of endothelin-induced constriction in pial arteries from human brain. Stroke 1999, 30:638-643.
34. Johnstrom P., Fryer T.D., Richards H.K., Harris N.G., Barret O., Clark J.C., et al. Positron emission tomography using 18F-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ET B receptors in vivo. Br J Pharmacol 2005, 144:115-122.
35. Maguire J.J., Davenport A.P. No alteration in vasoconstrictor endothelin-B-receptor density or function in human coronary artery disease. J Cardiovasc Pharmacol 2000, 36(Suppl 1):S380-S381.
36. Love M.P., Haynes W.G., Webb D.J., McMurray J.J. Venous endothelin receptor function in patients with chronic heart failure. Clin Sci (Lond) 2000, 98:65-70.
37. Love M.P., Ferro C.J., Haynes W.G., Plumpton C., Davenport A.P., Webb D.J., et al. Endothelin receptor antagonism in patients with chronic heart failure. Cardiovasc Res 2000, 47:166-172.
38. Gauquelin G., Thibault G., Garcia R. Characterization of renal glomerular endothelin receptors in the rat. Biochem Biophys Res Commun 1989, 164:54-57.
39. Rebibou J.M., He C.J., Delarue F., Peraldi M.N., Adida C., Rondeau E., et al. Functional endothelin 1 receptors on human glomerular podocytes and mesangial cells. Nephrol Dial Transplant 1992, 7:288-292.
40. Ortmann J., Amann K., Brandes R.P., Kretzler M., Munter K., Parekh N., et al. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 2004, 44:9749-9781.
41. Barton M. Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans. Biochim Biophys Acta 2010, 1802:1203-1213.
42. Neuhofer W., Pittrow D. Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence. Eur J Clin Invest 2009, 39(Suppl 2):50-67.
43. Kelland N.F., Kuc R.E., McLean D.L., Azfer A., Bagnall A.J., Gray G.A., et al. Endothelial cell-specific ETB receptor knockout: autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1. Can J Physiol Pharmacol 2010, 88:644-651.
44. Fukuroda T., Fujikawa T., Ozaki S., Ishikawa K., Yano M., Nishikibe M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994, 199:1461-1465.
45. Plumpton C., Ferro C.J., Haynes W.G., Webb D.J., Davenport A.P. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br J Pharmacol 1996, 119:311-314.
46. Montanari A., Carra N., Perinotto P., Iori V., Fasoli E., Biggi A., et al. Renal hemodynamic control by endothelin and nitric oxide under angiotensin II blockade in man. Hypertension 2002, 39:715-720.
47. Montanari A., Biggi A., Carra N., Fasoli E., Calzolari M., Corsini F., et al. Endothelin-A blockade attenuates systemic and renal hemodynamic effects of L-NAME in humans. Hypertension 2000, 35:518-523.
48. Bagnall A.J., Kelland N.F., Gulliver-Sloan F., Davenport A.P., Gray G.A., Yanagisawa M., et al. Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt. Hypertension 2006, 48:286-293.
49. Seyrantepe V., Hinek A., Peng J., Fedjaev M., Ernest S., Kadota Y., et al. Enzymatic activity of lysosomal carboxypeptidase (cathepsin) A is required for proper elastic fiber formation and inactivation of endothelin-1. Circulation 2008, 117:1973-1981.
50. Gariepy C.E., Ohuchi T., Williams S.C., Richardson J.A., Yanagisawa M. Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest 2000, 105:925-933.
51. Ge Y., Bagnall A., Stricklett P.K., Strait K., Webb D.J., Kotelevtsev Y., et al. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol 2006, 291:F1274-F1280.
52. Pedersen E.B., Thomsen I.M., Fjordside L.S. Effect of BQ-123, an endothelin antagonist, on renal hemodynamics, tubular function, vasoactive hormones, and blood pressure in healthy humans: a dose response study. Am J Hypertens 2005, 18:1578-1585.
53. Goddard J., Eckhart C., Johnston N.R., Cumming A.D., Rankin A.J., Webb D.J. Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism. J Am Soc Nephrol 2004, 15:2601-2610.
54. Dhaun N., Ferro C.J., Davenport A.P., Haynes W.G., Goddard J., Webb D.J. Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrol Dial Transplant 2007, 22:3228-3234.
55. Goddard J., Johnston N.R., Hand M.F., Cumming A.D., Rabelink T.J., Rankin A.J., et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004, 109:1186-1193.
56. Dhaun N., Macintyre I.M., Melville V., Lilitkarntakul P., Johnston N.R., Goddard J., et al. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 2009, 54:113-119.
57. Mann J.F., Green D., Jamerson K., Ruilope L.M., Kuranoff S.J., Littke T., et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010, 21. ASCEND Study Group, 527-3.
58. Don G.W., Joseph F., Celermajer D.S., Corte T.J. Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan. Intern Med J 2012, 42:1351-1354.
59. Kuc R.E., Carlebur M., Maguire J.J., Yang P., Long L., Toshner M., et al. Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension. Life Sci 2014, 118:391-396.
60. Zolk O., Quattek J., Sitzler G., Schrader T., Nickenig G., Schnabel P., et al. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation 1999, 99:2118-2123.
61. Opitz C.F., Ewert R., Kirch W., Pittrow D. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?. Eur Heart J 2008, 29:1936-1948.
62. Vachiéry J.L., Davenport A. The endothelin system in pulmonary and renal vasculopathy: les liaisons dangereuses. Eur Respir Rev 2009, 18:260-271.
63. Allcock G.H., Warner T.D. Inhibition of ETB receptors limits the efficacy of nonselective endothelin antagonists in vivo. J Cardiovasc Pharmacol 1995, 26(Suppl 3):S177-S179.
64. Ohkita M., Takaoka M., Matsumura Y. Drug discovery for overcoming chronic kidney disease (CKD): the endothelin ET B receptor/nitric oxide system functions as a protective factor in CKD. J Pharmacol Sci 2009, 109:7-13.
65. Maguire J.J., Davenport A.P. Importance of sub-type selectivity for endothelin receptor antagonists in the human vasculature. Translational vascular medicine: pathogenesis, diagnosis, and treatment 2012, Springer, London, 151-72. D. Abraham, C. Handler, M. Dashwood, G. Coghlan (Eds.).
66. Maguire J.J., Kuc R.E., Davenport A.P. Defining the affinity and receptor sub-type selectivity of four classes of endothelin antagonists in clinically relevant human cardiovascular tissues. Life Sci 2012, 91:681-686.
67. Vizza C.D., Fedele F., Pezzuto B., Rubin L.J. Safety and efficacy evaluation of ambrisentan in pulmonary hypertension. Expert Opin Drug Saf 2012, 11:1003-1011.
68. Stuart D., Chapman M., Rees S., Woodward S., Kohan D.E. Myocardial, smooth muscle, nephron, and collecting duct gene targeting reveals the organ sites of endothelin A receptor antagonist fluid retention. J Pharmacol Exp Ther 2013, 346:182-189.
69. Treiber A., Aanismaa P., de Kanter R., Delahaye S., Treher M., Hess P., et al. Macitentan does not interfere with hepatic bile salt transport. J Pharmacol Exp Ther 2014, 350:130-143.
70. Dingemanse J., Sidharta P.N., Maddrey W.C., Rubin L.J., Mickail H. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf 2014, 13:391-405.
71. Palmer M.J. Endothelin receptor antagonists: status and learning 20 years on. Prog Med Chem 2009, 47:203-237.
72. Dhaun N., Moorhouse R., MacIntyre I.M., Melville V., Oosthuyzen W., Kimmitt R.A., et al. Diurnal variation in blood pressure and arterial stiffness in chronic kidney disease: the role of endothelin-1. Hypertension 2014, 64:296-304.
73. Dhaun N., Melville V., Blackwell S., Talwar D.K., Johnston N.R., Goddard J., et al. Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. J Am Soc Nephrol 2013, 24:31-36.
74. Pulido T., Adzerikho I., Channick R.N., Delcroix M., Galie N., Ghofrani H.A., et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013, 369:809-818.
75. Sidharta P.N., van Giersbergen P.L., Halabi A., Dingemanse J. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol 2011, 67:977-984.
76. Iglarz M., Binkert C., Morrison K., Fischli W., Gatfield J., Treiber A., et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008, 327:736-745.
77. Sidharta P.N., Lindegger N., Ulc I., Dingemanse J. Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment. J Clin Pharmacol 2014, 54:291-300.
78. Sidharta P.N., van Giersbergen P.L., Safety Dingemanse J. tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. J Clin Pharmacol 2013, 53:1131-1138.
79. Bruderer S., Hopfgartner G., Seiberling M., Wank J., Sidharta P.N., et al. Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica 2012, 42:901-910.
80. Gatfield J., Mueller Grandjean C., Sasse T., Clozel M., Nayler O. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One 2012, 7:e47662.
81. Patel T.1, McKeage K. Macitentan: first global approval. Drugs 2014, 74:127-133.
82. de Zeeuw D., Coll B., Andress D., Brennan J.J., Tang H., Houser M. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 2014, 25:1083-1093.
83. Study Of Diabetic Nephropathy With Atrasentan (SONAR). Available from: . Accessed: August 10, 2014. http://clinicaltrials.gov/show/NCT01858532.